The US and Europe have reached the same conclusion in more than 90% of marketing authorisation decisions for new medicines, according to a report from the European Medicines Agency.
Several pharma bodies have signed non-disclosure agreements which prevent them from disclosing the UK government’s plans for a no-deal Brexit.
The US Court of Appeals for the Federal Circuit yesterday, August 15, blocked Actavis’s attempt to market a generic version of Nalpropion Pharmaceuticals’ weight-loss drug Contrave.
Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.
Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.
Ireland-based Jazz Pharma has acquired Virginia-based Cavion in a deal that values the clinical-stage biotech company at up to $312.5 million.
Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, has taken the Alzheimer's Institute of America to court over its “malicious” prosecution of a patent infringement case.
Allergan has filed a motion asking for its “trade secrets” to be removed from evidence in a dispute over its wrinkle treatment, Botox.
Sandoz has confirmed that it plans to appeal against a decision that upheld the validity of two of Amgen’s patents for its arthritis treatment Enbrel, effectively blocking the launch of Sandoz’s biosimilar version.
The US Court of Appeals for the Federal Circuit last week affirmed two findings that Dr Reddy’s and Hospira had infringed Eli Lilly’s cancer drug Alimta.